Arrowhead Pharmaceuticals Inc. has announced its intention to offer $500 million aggregate principal amount of convertible senior notes due 2032 in a public offering. In addition to the debt offering, the company plans to offer $200 million of common stock in a separate public offering. Arrowhead also expects to grant underwriters a 30-day option to purchase up to an additional $75 million of notes and up to an additional $30 million of common stock to cover over-allotments. Proceeds from the note offering will be used in part to fund capped call transactions and for general corporate purposes, including research and development, commercialization activities, and potentially to prepay loans under its existing credit facility. The completion of each offering is not contingent on the other.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260106505985) on January 06, 2026, and is solely responsible for the information contained therein.